Quanterix Corporation Q3 2026 Earnings Call - QUANTERIX CORP

Financial Performance:

• Reported Q3 2026 total revenue of $35 million, representing a 6.3% sequential increase (exceeding prior guidance) but a 13.1% year-over-year decline; pro forma YoY decline narrowed to 8.6%.
• Non-GAAP gross margin improved 150 basis points to 47.4%, driven by acquisition synergies and cost optimization despite lower volume; GAAP gross margin was 38.6%.
• Net loss narrowed to $21.6 million (an $11.9 million improvement YoY); Adjusted EBITDA loss widened slightly to $12.2 million due to volume, offset by lower operating expenses.
• Cash burn was $16.2 million in the quarter; ending cash balance was approximately $80.7 million with no debt.
• Operating expenses decreased 27.2% YoY to $36 million; Non-GAAP OpEx was $35.4 million, down 2.8% sequentially.

Guidance and Future Outlook:

• Revised full-year 2026 revenue guidance to $142–$146 million; expects Q4 revenue to approximate $40 million based on strong accelerator bookings and improved commercial execution.
• Maintains full-year non-GAAP gross margin guidance of 48–50%.
• Projects ending 2026 cash balance of approximately $70 million; no debt expected.
• Reaffirms medium-term goal of achieving cash flow break-even in 2027, contingent on revenue growth and margin expansion.
• Anticipates 2027 revenue growth to be driven by the ramp-up of the new commercial organization, the 510K submission for the HDX platform, and expanded diagnostic partnerships.

Business Segments and Product Lines:

• Spatial: Revenue grew double-digits sequentially; consumables reached near-record levels. Launched Phenocycler 2.0 Molecular Barcoding Kit and will introduce TIME and HyPlex ADC panels in early 2027.
• Simoa (Samoa): Revenue increased slightly sequentially, driven by new instrument placements and new assay launches (APOE4 prototyping and IL-18 kits).
• Accelerator Lab: Bookings grew for the second consecutive quarter with a book-to-bill ratio approaching 2:1; revenue flat sequentially excluding terminated program impact.
• Diagnostics: "Lucent AD Complete" test volume doubled sequentially; established new partnerships with Sherman Abrams and TruPath labs covering 14 U.S. states.
• Instrument Placements: Strong sequential growth in U.S. Spatial and overall Americas region (high teens growth), while EMEA remained soft due to seasonality.

Market and Competitive Landscape:

• Identified a "national movement" supporting blood-based biomarker testing, highlighted by Florida's Medicaid coverage approval for $484 per test effective November 1st.
• Launched partnerships in China with Ovita Biological Technology to distribute HDX/SRX testing kits for four biomarkers.
• Management notes that FDA approvals by competitors (Roche, C2N) legitimize the Alzheimer's biomarker market, though Quanterix maintains a differentiated 5-marker test with lower indeterminate rates.
• Spatial oncology expansion targets "Hallmarks of Cancer" framework to address customer needs for combination biology readouts in immuno-oncology.

Risks and Challenges:

• Continued market softness in EMEA and academic sectors, though Spatial demand remains resilient.
• Transition period for new commercial leadership; full impact of organizational restructuring expected to materialize in 2027.
• Regulatory uncertainty regarding FDA timing for the 510K submission on the HDX platform and the pending review of the multi-biomarker Alzheimer's test.
• Reimbursement dependency: Current diagnostic revenue growth relies on commercial partnerships and payer coverage, which may vary by state and market access dynamics.
• Working capital movements and timing of expenditures impacting cash usage.

Management Commentary and Tone:

• Tone is confident and cautiously optimistic, framing Q3 results as the "first step in restoring growth" and reversing the previous year's decline trend.
• Management highlighted the strategic "laser focus" on commercial execution following the appointment of a new Chief Commercial Officer (Jim Guth) and Chief Medical Officer (Dr. Yuri Fesco).
• Emphasized the shift to a product-based sales structure to improve specialty focus and customer relationships.
• Expressed strong conviction in the scalability of the diagnostics business and the accretive margins of the Accelerator Lab.

Analyst Questions and Answers:

• Kyle Mixon (Canaccord Genuity): Questioned the divergence between Spatial consumable growth and softness in Simoa consumables; Management attributed the improvement to new assay launches (APOE4, IL-18) and a refocused commercial team. Confirmed that diagnostic revenue is immaterial but volume is doubling.
• Dan Brennan (TD Cowen): Asked for Q4 guidance breakdown and 2027 profitability drivers; Management cited granular pipeline builds, a dedicated Accelerator team, and revenue growth as the primary levers for the $40M Q4 target and 2027 break-even.
• Puneet Suda (Leerink Partners): Inquired about Accelerator bookings numbers and FDA timeline; Management disclosed ~$2.9M in Q3 bookings for Accelerator (up significantly), with conversion expected in Q4. Reiterated productive FDA discussions and optimism for clearance, while noting Florida Medicaid pricing is $484/test.

Other Key Points:

• Florida House Bill 885 approved blood-based Alzheimer's testing coverage for over 4 million Medicaid residents, retroactive to July 2026.
• The company is building a "total neurological brain health diagnostic assessment portfolio" beyond Alzheimer's, targeting Parkinson's, Huntington's, and traumatic brain injuries.
• The Accelerator Lab has added a dedicated sales team of seven to drive global pharma partnerships.
• 510K application for the HDX instrument as an IVD remains on track for a 2027 submission.
• Investor relations to participate in the Piper Sandler Health Care Conference in early December.